Skip to main content

Research

VUMC-led network to focus on polygenic risk for common diseases

Jul. 1, 2020—With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.

Read more


Adams to lead TIPs-funded, soldier-inspired innovation hub

Jun. 30, 2020—A new innovation incubator will amplify existing collaborations among researchers and soldiers, building on Vanderbilt's partnership agreement with Army Futures Command.

Read more


Nine faculty receive 2020 Research Scholar and Discovery grants

Jun. 29, 2020—Research Scholar Grants are one of Vanderbilt’s primary investments to advance faculty research, scholarship and creative expression, while Discovery Grants support new ideas and cutting-edge scholarship that possess high potential for future external support.

Read more


VISE researchers receive $3.1M grant for customizable cochlear implant programming

Jun. 26, 2020—A team of Vanderbilt University and Vanderbilt University Medical Center researchers has received a $3.1 million NIH grant to develop advanced patient-specific cochlear implant stimulation models for customized implant programming.

Read more


VICTR named to key role to streamline COVID-19 research response

Jun. 24, 2020—The Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at Vanderbilt University Medical Center (VUMC), has been named Administrative Coordinating Center (ACC) of a national effort to streamline the research response to life-threatening lung and heart problems caused by COVID-19.

Read more


Study shows better option for treatment of inoperable anal cancer

Jun. 24, 2020—People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

Read more


Data Science Institute big data model to help Monroe Carell Jr. Children’s Hospital prepare for patient needs during pandemic and beyond

Jun. 24, 2020—Vanderbilt's Data Science Institute researchers are developing a model to use big data to address the impact of COVID-19 on policies, procedures, and resources now and in the future. The tool will help Monroe Carell Jr. Children's Hospital at Vanderbilt evaluate short- and long-term resource needs in order to be fully prepared to meet patients' needs.

Read more


Study finds zinc doesn’t reduce mortality, other health risks, for heavy alcohol users living with HIV/AIDS

Jun. 24, 2020—Zinc supplementation did not reduce mortality, cardiovascular risk, levels of inflammation or microbial translocation among people with heavy alcohol use living with HIV/AIDS, according to a Vanderbilt-led study.

Read more


Glaucoma drug studied to prevent lung Infection in COVID-19 patients

Jun. 24, 2020—Vanderbilt University Medical Center is evaluating razuprotafib, a drug used to treat glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.

Read more


A connection to schizophrenia

Jun. 23, 2020—The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found.

Read more


Single mutation causes seizure disorder

Jun. 22, 2020—A single mutation in one gene can impair inhibitory signaling in the brain and cause multiple types of seizures and behavioral abnormalities.

Read more


Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19

Jun. 21, 2020—The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. 

Read more


VIEW MORE EVENTS >